NPCE vs. INMD, CDRE, MDXG, BLFS, RXST, AORT, EMBC, PLSE, LQDA, and ESTA
Should you be buying NeuroPace stock or one of its competitors? The main competitors of NeuroPace include InMode (INMD), Cadre (CDRE), MiMedx Group (MDXG), BioLife Solutions (BLFS), RxSight (RXST), Artivion (AORT), Embecta (EMBC), Pulse Biosciences (PLSE), Liquidia (LQDA), and Establishment Labs (ESTA). These companies are all part of the "medical equipment" industry.
NeuroPace vs.
InMode (NASDAQ:INMD) and NeuroPace (NASDAQ:NPCE) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, dividends, media sentiment, risk, valuation, profitability, community ranking, analyst recommendations and institutional ownership.
InMode received 133 more outperform votes than NeuroPace when rated by MarketBeat users. Likewise, 73.85% of users gave InMode an outperform vote while only 58.33% of users gave NeuroPace an outperform vote.
In the previous week, InMode and InMode both had 3 articles in the media. NeuroPace's average media sentiment score of 1.04 beat InMode's score of 0.21 indicating that NeuroPace is being referred to more favorably in the news media.
InMode has higher revenue and earnings than NeuroPace. NeuroPace is trading at a lower price-to-earnings ratio than InMode, indicating that it is currently the more affordable of the two stocks.
InMode currently has a consensus target price of $22.40, indicating a potential upside of 33.41%. NeuroPace has a consensus target price of $15.00, indicating a potential upside of 25.31%. Given InMode's higher possible upside, research analysts clearly believe InMode is more favorable than NeuroPace.
68.0% of InMode shares are owned by institutional investors. Comparatively, 78.8% of NeuroPace shares are owned by institutional investors. 6.9% of InMode shares are owned by company insiders. Comparatively, 22.2% of NeuroPace shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
InMode has a beta of 2.12, suggesting that its stock price is 112% more volatile than the S&P 500. Comparatively, NeuroPace has a beta of 2.02, suggesting that its stock price is 102% more volatile than the S&P 500.
InMode has a net margin of 36.26% compared to NeuroPace's net margin of -36.74%. InMode's return on equity of 21.46% beat NeuroPace's return on equity.
Summary
InMode beats NeuroPace on 11 of the 17 factors compared between the two stocks.
Get NeuroPace News Delivered to You Automatically
Sign up to receive the latest news and ratings for NPCE and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
NeuroPace Competitors List
Related Companies and Tools
This page (NASDAQ:NPCE) was last updated on 1/21/2025 by MarketBeat.com Staff
Free NPCE Stock Alerts